Basiri Mohsen, Pahlavanneshan Saghar
Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. Email:
Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Cell J. 2021 Nov;23(6):717-721. doi: 10.22074/cellj.2021.7299. Epub 2021 Nov 23.
Placental alkaline phosphatase (PLAP) is a membrane enzyme mainly expressed in the placenta. PLAP is shown to be expressed in ovarian cancer (OV), however, there is little known about its expression in other cancers. Using gene and protein expression deposited data, we surveyed PLAP expression across malignant and normal human tissues to explore the potential of PLAP as an immunotherapy target. We detected more than two-fold increased PLAP expression in multiple solid tumors including ovarian cancer, testicular germ cell tumors (TGCT), and uterine corpus endometrial carcinoma (UCEC) compared with matched normal tissues. We also showed association of PLAP expression with high mortality pancreatic adenocarcinoma (PAAD). Altogether, our results suggest that PLAP can be a promising target for immunotherapy of multiple cancers, especially OV, TGCT, and UCEC.
胎盘碱性磷酸酶(PLAP)是一种主要在胎盘中表达的膜酶。已表明PLAP在卵巢癌(OV)中表达,然而,对于其在其他癌症中的表达知之甚少。利用已存档的基因和蛋白质表达数据,我们调查了PLAP在恶性和正常人体组织中的表达情况,以探索PLAP作为免疫治疗靶点的潜力。与匹配的正常组织相比,我们在包括卵巢癌、睾丸生殖细胞肿瘤(TGCT)和子宫内膜癌(UCEC)在内的多种实体瘤中检测到PLAP表达增加了两倍以上。我们还表明PLAP表达与高死亡率的胰腺腺癌(PAAD)有关。总之,我们的结果表明PLAP可能是多种癌症免疫治疗的一个有前景的靶点,尤其是卵巢癌、睾丸生殖细胞肿瘤和子宫内膜癌。